Low-dose oral interferon could be more effective than other
treatments for reducing the risk for hepatitis C virus relapse in
patients with mild liver fibrosis, according to a recent study.
In a double blind study, researchers analyzed 169 chronic HCV patients with genotype 1b who had been treated with pegylated interferon-alfa
and ribavirin. They were randomly assigned interferon-alfa lozenges at
500 IU per day (n=59), 1,500 IU per day (n=53) or placebo (n=57) for 24